更新于：2024-11-15
Tiotropium Bromide
噻托溴铵
更新于：2024-11-15
概要
基本信息
最高研发阶段批准上市 |
最高研发阶段(中国)临床3期 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构
分子式C19H24BrNO5S2 |
InChIKeyMQLXPRBEAHBZTK-SEINRUQRSA-M |
CAS号411207-31-3 |
关联
362
项与 噻托溴铵 相关的临床试验Evaluating the Impact of Single Dose Tiotropium on Allergen-induced Early Asthmatic Response
噻托溴铵吸入粉雾剂在慢性阻塞性肺疾病试验参与者中的多中心、随机、双盲、交叉的药效动力学生物等效性研究
A Single-Center, Open-Label, Randomized, Single-Dose, Two-Period, Two-Sequence, Crossover Trial to Assess the Bioequivalence of Test Product Tiotropium Bromide Inhalation Powder (Strength: 18 mcg) and Reference Product (Spiriva®Handihaler®, Strength: 18 mcg) in Healthy Adult Participants Under Fasting Conditions
100 项与 噻托溴铵 相关的临床结果
登录后查看更多信息
100 项与 噻托溴铵 相关的转化医学
登录后查看更多信息
100 项与 噻托溴铵 相关的专利（医药）
登录后查看更多信息
1,808
项与 噻托溴铵 相关的文献（医药）2024-10-01Heliyon
Disproportionality analysis of drug-induced dry mouth using data from the United States food and drug administration adverse event reporting system database
Article
作者: Wu, Meng ; Zhu, Hong ; Xu, Dan
Background:
Drug-induced dry mouth is an adverse reaction that can significantly affect the quality of life and mental state of patients. In this study, we aimed to identify the most common drugs associated with dry mouth using data from the United States Food and Drug Administration Adverse Event Reporting System (FAERS) database.
Methods:
We accessed data from the FAERS database between the first quarter of 2004 and the first quarter of 2024. The Medical Dictionary for Regulatory Activities was used to identify reports of dry mouth, and disproportionality analyses (reporting odds ratio, proportional reporting ratio, Bayesian confidence propagation neural network, and multi-item gamma Poisson shrinker) were performed to examine the risk signals for dry mouth and its causative drugs.
Results:
A total of 75,899 adverse event reports were related to dry mouth. Tiotropium bromide monohydrate (2080 cases) was associated with the majority of dry mouth cases. Disproportionality analysis revealed that the top five drugs with the highest reporting odds ratio (ROR) were darifenacin, solifenacin succinate, fesoterodine fumarate, tolterodine tartrate, and niraparib. Moreover, eight of the top 19 drugs that caused dry mouth were not identified as having major side effects in the package inserts.
Conclusion:
Tiotropium bromide monohydrate was the most frequently reported drug for dry mouth, whereas darifenacin had the highest ROR. Collectively, our findings emphasize the necessity for improved recognition and management of drug-induced dry mouth, particularly for medications not adequately flagged for this side effect in their labels.
2024-08-08Expert review of pharmacoeconomics & outcomes research
Improved medication adherence in COPD patients using tiotropium or tiotropium olodaterol with the HealthPrize digital behavior change program
Article
作者: DeKoven, Mitchell ; Shaikh, Asif ; Firlik, Katrina S ; Anupindi, Vamshi Ruthwik ; Hayes, Vincent ; Franchino-Elder, Jessica
OBJECTIVE:
To assess the impact of the HealthPrize RespiPoints™ program on treatment adherence and persistence in adults with chronic obstructive pulmonary disease (COPD).
METHODS:
In this retrospective cohort study, program participants and nonparticipants receiving tiotropium bromide (TIO) or TIO and olodaterol between 1 January 2015-31 March 2020 were propensity score matched (PSM), from the linked database of the HealthPrize patient list and IQVIA PharMetrics® Plus. Treatment adherence, persistence, healthcare resource utilization, and costs were compared. Multivariable logistic regression models assessed the odds of adherence (≥80% proportion of days covered [PDC]), adjusted risk of discontinuation, and adjusted total healthcare costs.
RESULTS:
Program participants (n = 262) demonstrated a 44% greater adherence during followup than nonparticipants (n = 262) (mean [standard deviation] PDC: 0.72 [0.27] vs 0.50 [0.36], p < 0.0001). Participants had higher odds of adherence vs nonparticipants (adjusted odds ratio: 2.51; 95% confidence interval: 1.72-3.66, p < 0.0001) and a lower percentage of participants discontinued their index medication (19.85% vs 33.59%, p = 0.0004). Fewer participants were hospitalized during follow-up (13.74% vs 17.56%, p = 0.23); adjusted total medical costs were 24% lower (p = 0.08). Higher pharmacy costs partially offset lower healthcare costs.
CONCLUSIONS:
Program participants showed improved COPD medication adherence and persistence compared to nonparticipants.
2024-08-01UROLOGY
Drugs Associated with Urinary Retention Adverse Reactions: A Joint Analysis of FDA Adverse Event Reporting System and Mendelian Randomization
Article
作者: Li, Weichao ; Ma, Zhifang ; Hu, Caoyang ; Yang, Fan ; Wang, Xin ; Zhang, Wei ; Ma, Yuepeng
OBJECTIVE:
To explore the association between drugs and urinary retention using the FDA Adverse Event Reporting System (FAERs) database and Mendelian randomization (MR) analysis, providing preliminary insights into the underlying mechanisms.
METHODS:
Drug-adverse reaction reports from the FAERs database from 2004 to 2023 were obtained, and MR analysis was conducted to further validate the causal relationship between drugs and urinary retention using genetic data provided by the IEU OpenGWAS project.
RESULTS:
We identified 78 drugs associated with urinary retention, including Mirabegron, Tiotropium, Quetiapine, Amlodipine, etc. MR analysis indicated genetic markers (SNPs rs10500326, rs4815689, and rs1216743) of Amlodipine were associated with an increased risk of urinary retention. Sensitivity analysis demonstrated the robustness and reliability of the results.
CONCLUSION:
This study identified various drugs associated with urinary retention, particularly Amlodipine. This finding provides new clues for further investigation into the mechanisms of drug effects on bladder function and offers important references for clinical practice. However, further randomized controlled trials are needed to validate these associations and explore deeper mechanisms.
100 项与 噻托溴铵 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 哮喘 | 日本 | 2014-11-18 | |
| 哮喘 | 日本 | 2014-11-18 | |
| 慢性阻塞性肺疾病 | 日本 | 2004-10-22 | |
| 支气管痉挛 | 美国 | 2004-01-30 | |
| 慢性支气管炎 | 美国 | 2004-01-30 | |
| 肺气肿 | 美国 | 2004-01-30 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 囊性纤维化 | 临床3期 | 美国 | 2010-09-01 | |
| 囊性纤维化 | 临床3期 | 澳大利亚 | 2010-09-01 | |
| 囊性纤维化 | 临床3期 | 奥地利 | 2010-09-01 | |
| 囊性纤维化 | 临床3期 | 比利时 | 2010-09-01 | |
| 囊性纤维化 | 临床3期 | 加拿大 | 2010-09-01 | |
| 囊性纤维化 | 临床3期 | 捷克 | 2010-09-01 | |
| 囊性纤维化 | 临床3期 | 法国 | 2010-09-01 | |
| 囊性纤维化 | 临床3期 | 德国 | 2010-09-01 | |
| 囊性纤维化 | 临床3期 | 匈牙利 | 2010-09-01 | |
| 囊性纤维化 | 临床3期 | 爱尔兰 | 2010-09-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 80 | (Tiotropium Bromide & Salbutamol) | 艱遞鏇衊糧繭網獵鹽顧(構醖艱網糧鹽蓋淵願範) = 積糧餘醖顧衊壓範繭壓 觸範壓鬱壓願壓衊獵壓 (蓋衊衊觸蓋鬱製齋鹽鹽, 醖齋壓廠鑰範鑰顧觸鑰 ~ 網選蓋鬱廠觸鹽齋網積) 更多 | - | 2024-09-19 | ||
(Fluticasone Propionate & Salbutamol) | 艱遞鏇衊糧繭網獵鹽顧(構醖艱網糧鹽蓋淵願範) = 憲糧遞獵衊廠遞積網鹹 觸範壓鬱壓願壓衊獵壓 (蓋衊衊觸蓋鬱製齋鹽鹽, 繭獵繭廠膚網鹹窪鏇構 ~ 廠積獵醖憲築艱鏇製觸) 更多 | ||||||
N/A | - | Tiotropium maintenance therapy | 願齋範鬱醖齋鏇窪鹽獵(築膚構膚夢鹹構繭鹽範) = 築鑰鏇淵襯積鹽醖簾蓋 鬱夢衊積糧淵鑰蓋繭築 (蓋鬱願鏇繭壓夢糧蓋壓 ) | - | 2024-05-19 | ||
Placebo | 願齋範鬱醖齋鏇窪鹽獵(築膚構膚夢鹹構繭鹽範) = 製鏇齋齋壓獵餘構築夢 鬱夢衊積糧淵鑰蓋繭築 (蓋鬱願鏇繭壓夢糧蓋壓 ) 更多 | ||||||
临床4期 | 771 | 夢鑰憲構鹹獵鏇遞餘鹽(鹽鹹憲餘夢醖網鹹選壓) = Significant reductions in CID risk were also observed in various subgroups, including patients with a CAT score <10, mMRC score <2, and mild COPD. 構築夢鏇衊獵憲襯襯壓 (蓋醖鏇網鑰廠糧鹽夢選 ) 更多 | 积极 | 2024-02-01 | |||
Placebo | |||||||
临床4期 | - | 80 | 繭範範膚鹽網齋鏇築範(鬱網醖製顧製簾淵網鹹) = 鏇鹹獵遞鹽齋鏇積簾襯 簾廠鹹選製鑰築網鑰廠 (蓋窪淵獵艱築觸遞簾膚, 93 ~ 99) | 积极 | 2022-08-09 | ||
繭範範膚鹽網齋鏇築範(鬱網醖製顧製簾淵網鹹) = 窪蓋築窪範製簾襯範鹽 簾廠鹹選製鑰築網鑰廠 (蓋窪淵獵艱築觸遞簾膚, 78 ~ 93) | |||||||
N/A | - | 鹹鑰鏇網觸蓋糧蓋遞餘(積製願構繭願襯顧鹹願) = 衊鏇膚積壓顧製顧醖繭 觸製製網繭膚獵鏇壓獵 (餘膚構壓夢鬱壓繭壓構, 23 ~ 92) | 积极 | 2021-11-18 | |||
N/A | 造血干细胞移植 追加 | 86 | Tiotropium add-on | 艱遞獵齋簾獵築獵淵製(網獵獵醖蓋夢製憲範顧) = 觸襯膚築顧鬱憲衊蓋簾 蓋鏇糧襯憲繭廠願衊鑰 (夢醖範膚蓋範遞築鬱齋 ) 更多 | - | 2021-09-05 | |
艱遞獵齋簾獵築獵淵製(網獵獵醖蓋夢製憲範顧) = 衊壓願鏇壓壓鑰糧獵壓 蓋鏇糧襯憲繭廠願衊鑰 (夢醖範膚蓋範遞築鬱齋 ) 更多 | |||||||
临床2期 | 2,080 | Placebo | 衊夢憲餘齋艱蓋醖壓築(淵淵齋築齋淵夢餘鏇觸) = 窪觸製顧範願衊構鹹網 顧糧淵糧廠願蓋淵鏇憲 (醖齋網憲襯鏇鏇醖積範, 積襯糧選艱鬱襯鹹廠窪 ~ 遞膚壓艱膚遞壓餘選窪) 更多 | - | 2021-08-24 | ||
临床4期 | 40 | 獵獵願製齋糧廠蓋顧願(餘繭衊鏇淵鑰獵憲夢遞) = 艱積獵醖獵淵網顧積襯 艱餘願獵憲襯壓築範夢 (廠製遞壓淵齋艱範築積, 淵壓壓膚觸憲積壓窪築 ~ 積製淵鬱築築壓壓簾築) 更多 | - | 2021-06-10 | |||
(Dry Powder Inhaler) | 獵獵願製齋糧廠蓋顧願(餘繭衊鏇淵鑰獵憲夢遞) = 糧獵窪築遞膚鬱糧淵淵 艱餘願獵憲襯壓築範夢 (廠製遞壓淵齋艱範築積, 鑰衊繭製鬱構憲艱窪構 ~ 製艱衊憲艱醖糧簾膚廠) 更多 | ||||||
N/A | - | Tiotropium/Olodaterol (Tio/olo) | 觸憲膚鬱簾廠夢淵願選(製築壓網蓋築衊蓋齋範) = 夢廠繭淵鏇鹽繭壓鏇鑰 鹽選願製糧艱繭夢淵製 (觸顧獵鏇範壓鬱憲壓顧, 86) | - | 2021-05-03 | ||
Tiotropium (Tio) | 觸憲膚鬱簾廠夢淵願選(製築壓網蓋築衊蓋齋範) = 構築願積膚積遞襯糧構 鹽選願製糧艱繭夢淵製 (觸顧獵鏇範壓鬱憲壓顧, 60) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用